Literature DB >> 16237810

Fatty liver and drugs.

A Grieco1, A Forgione, L Miele, V Vero, A V Greco, A Gasbarrini, G Gasbarrini.   

Abstract

Drug-induced liver diseases (DILD) are clinico-pathologic patterns of liver injury caused by drugs or other foreign compounds. Steatohepatitis is a rare form of DILD, and drugs account for fewer than 2% of non-alcoholic steatohepatitis (NASH). Drugs known to be capable of inducing steatosis and steatohepatitis can be divided into three broad groups: those that cause steatosis and steatohepatitis independently (e.g., amiodarone, perhexiline maleate); drugs which can precipitate latent NASH (e.g., tamoxifen); drugs whic duce sporadic events of steatosis/steatohepatitis (e.g., carbamazepine). Clinical DILD syndromes include acute viral hepatitis-like injury, acute liver failure, cholestatic hepatitis,liver disease with signs of hypersensitivity, autoimmune hepatitis-like injury, acute venous-Outflow obstruction, chronic cholestasis, ciirrhosis, steatosis and steatohepatitis. The clinical picture is by no means dependent on the mechanism of injury (direct hepatotoxicity, idiosyncratic reactions, hypersensitivity reactions). Reliable diagnosis of drug-induced liver disease requires demonstration of close correlation between the patient history and clinical, laboratory, and histological data.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16237810

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  12 in total

Review 1.  Drug-induced steatohepatitis.

Authors:  Ajit Dash; Robert A Figler; Arun J Sanyal; Brian R Wamhoff
Journal:  Expert Opin Drug Metab Toxicol       Date:  2016-10-27       Impact factor: 4.481

2.  Liver dysfunction revealed marked hyperdensity on computed tomography.

Authors:  Soichiro Ichikawa; Shigeru Kukuzawa
Journal:  Oman Med J       Date:  2012-07

Review 3.  Post-translational modification of pregnane x receptor.

Authors:  Jeff L Staudinger; Chenshu Xu; Arunima Biswas; Sridhar Mani
Journal:  Pharmacol Res       Date:  2011-03-21       Impact factor: 7.658

4.  Nonalcoholic fatty liver disease during valproate therapy.

Authors:  Alberto Verrotti; Giovanna Di Marco; Rosanna la Torre; Piernicola Pelliccia; Francesco Chiarelli
Journal:  Eur J Pediatr       Date:  2009-01-30       Impact factor: 3.183

Review 5.  Metabolic liver disease of obesity and role of adipose tissue in the pathogenesis of nonalcoholic fatty liver disease.

Authors:  Kamran Qureshi; Gary A Abrams
Journal:  World J Gastroenterol       Date:  2007-07-14       Impact factor: 5.742

Review 6.  Drug Induced Steatohepatitis: An Uncommon Culprit of a Common Disease.

Authors:  Liane Rabinowich; Oren Shibolet
Journal:  Biomed Res Int       Date:  2015-07-26       Impact factor: 3.411

7.  Model steatogenic compounds (amiodarone, valproic acid, and tetracycline) alter lipid metabolism by different mechanisms in mouse liver slices.

Authors:  Ewa Szalowska; Bart van der Burg; Hai-Yen Man; Peter J M Hendriksen; Ad A C M Peijnenburg
Journal:  PLoS One       Date:  2014-01-29       Impact factor: 3.240

8.  New microRNA Biomarkers for Drug-Induced Steatosis and Their Potential to Predict the Contribution of Drugs to Non-alcoholic Fatty Liver Disease.

Authors:  Mireia López-Riera; Isabel Conde; Laia Tolosa; Ángela Zaragoza; José V Castell; María J Gómez-Lechón; Ramiro Jover
Journal:  Front Pharmacol       Date:  2017-01-25       Impact factor: 5.810

9.  Liver injury induced by anticancer chemotherapy and radiation therapy.

Authors:  Y Maor; S Malnick
Journal:  Int J Hepatol       Date:  2013-07-17

10.  Uridine prevents fenofibrate-induced fatty liver.

Authors:  Thuc T Le; Yasuyo Urasaki; Giuseppe Pizzorno
Journal:  PLoS One       Date:  2014-01-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.